

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: June 30, 2012
Estimated Average burden hours per response: 4.0

1. Issuer's Identity				
CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Type	
0001293971				
Name of Issuer	==		C Limited Partnership	
Genetix Pharmaceuticals Inc			C Limited Liability Company	
Jurisdiction of			0	
Incorporation/Organization DELAWARE	7		General Partnership	
Year of Incorporation/Organiz	_ gation		Business Trust	
Over Five Years Ago	ation		Other	
Within Last Five Years (Specify Year) Yet to Be Formed				
2. Principal Place of Bu	siness and Co	ontact Inform	ation	
Name of Issuer				
Genetix Pharmaceuticals Inc				
Street Address 1		Street Address 2		
840 MEMORIAL DR 3RD FL				
City	State/Province/Count	try ZIP/Postal C	ode Phone No. of Issuer	
CAMBRIDGE	MA	02139	617-491-5601	
3. Related Persons				
Last Name	First Name		Middle Name	
Leschly	Nick			
Street Address 1		Street Address 2	ı	
840 Memorial Drive, 3rd Floo	or			
City	State/Province/Co	ountry	ZIP/Postal Code	
Cambridge	MA		02139	
Relationship: Exec	utive Officer	▼ Director	Promoter	
Clarification of Response (if Necess	ary)			
Loof Name	First No.		Middle News	
Last Name	First Name		Middle Name	
Polack	Axel			
Street Address 1		Street Address 2		
840 Memorial Drive, 3rd Floor				
City	State/Province/Co	ountry	ZIP/Postal Code	
Cambridge	MA		02139	

Relationship:	Executive Officer	☑ Director	Promoter	
Clarification of Respor	nse (if Necessary)		"	
Last Name	First Name		Middle Name	
Geraghty	James		A.	
Street Address 1		Street Address	2	
840 Memorial Driv	ve, 3rd Floor			
City	State/Province	ce/Country	ZIP/Postal Code	
Cambridge	MA		02139	
Relationship:	Executive Officer	✓ Director	Promoter	
Clarification of Respor	se (if Necessary)			
	,			
Last Name	First Name		Middle Name	
Mulder	Geert-Jan			
Street Address 1		Street Address	<u> </u>	
840 Memorial Driv	ve, 3rd Floor] ====		
City	State/Province	=ı ce/Country	ZIP/Postal Code	
Cambridge	MA		02139	
Γ	The sec	1		
Relationship:	Executive Officer	Director	Promoter	
Clarification of Respor	nse (if Necessary)			

4. Industry Group		
C Agriculture Banking & Financial Services C Commercial Banking C Insurance C Investing C Investment Banking C Pooled Investment Fund	Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care	C Retailing C Restaurants Technology C Computers C Telecommunications C Other Technology
Other Banking & Financial C Services Business Services Energy C Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy	Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	Travel C Airlines & Airports C Lodging & Conventions C Tourism & Travel Services C Other Travel C Other

5. Issuer Size				
Revenue Range	Aggregate Net Asset Value Range			
C No Revenues	No Aggregate Net Asset Value			
C \$1 - \$1,000,000	C \$1 - \$5,000,000			
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000			
\$5,000,001 - \$25,000,000	C \$25,000,001 - \$50,000,000			
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000			
Over \$100,000,000	Over \$100,000,000			
Decline to Disclose	C Decline to Disclose			
C Not Applicable	C Not Applicable			
6 Fodoral Evernation(s) and	d Evolucion(s) Claimed (coloct all that apply)			
	d Exclusion(s) Claimed (select all that apply)			
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505			
Rule 504 (b)(1)(i)	Rule 506			
Rule 504 (b)(1)(ii)	Securities Act Section 4(6)			
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)			
7. Type of Filing				
New Notice Date of First Sale	2010-03-05 First Sale Yet to Occur			
E				
Amendment				
8. Duration of Offering				
Does the Issuer intend this offering to last I	more than one year? C Yes 6 No			
9. Type(s) of Securities Offe	ered (select all that apply)			
Pooled Investment Fund Enterests	quity			
☐ Tenant-in-Common Securities ☐ D	ebt			
I Wilneral Property Securities IV	ption, Warrant or Other Right to			
A	cquire Another Security			
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	other (describe)			
10. Business Combination T	ransaction			
Is this offering being made in connection v combination transaction, such as a merger				
exchange offer?				
Clarification of Response (if Necessary)				
11. Minimum Investment				
Minimum investment accepted from any outside investor	\$ 0 USD			
12. Sales Compensation				
Recipient	Recipient CRD Number None			
(Associated) Broker or Dealer	None (Associated) Broker or Dealer CRD None Number			

Street Address 1	Street Address 2	
City	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation	All States	
13. Offering and Sales Amour	nts	
Total Offering Amount \$ 47412660	USD Indefinite	
Total Amount Sold \$ 29412661	USD	
otal Remaining to be \$\frac{17999999}{}	USD Indefinite	
Clarification of Response (if Necessary)		
14. Investors		
Select if securities in the offering has who do not qualify as accredited involved the offering Regardless of whether securities in sold to persons who do not qualify a total number of investors who alread	vestors, estors who already have invested in the offering have been or may be as accredited investors, enter the	6
15. Sales Commissions & Fire Provide separately the amounts of sales comexpenditure is not known, provide an estimation of the sales comexpenditure is not known, provide an estimation of the sales compared to the sales c	missions and finders' fees expenses,	=
Sales Commissions \$	USD	Estimate
Finders' Fees \$ 0	USD	Estimate
Clarification of Response (if Necessary)		
16. Use of Proceeds		
Provide the amount of the gross proceeds of payments to any of the persons required to be response to Item 3 above. If the amount is un amount.	ne named as executive officers, directors in the second of	ors or promoters in
	\$ 0 US	D Estimate
Clarification of Response (if Necessary)		
Signature and Submission		
Please verify the information you have below before signing and clicking S		
Terms of Submission	Commission to me this notice.	•
In submitting this notice, each Issuer name	d above is:	

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that the Issuer is not disqualified from relying on any Regulation D exemption it has identified in Item 6 above for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Genetix Pharmaceuticals Inc	/s/Nick Leschly	Nick Leschly	President	2010-03-18